Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. on July 23, 2019, reporting events that occurred on July 21, 2019. The Company is a Delaware corporation trading on the OTCQB Market under the symbol XCUR and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
The Board of Directors appointed two new Class II directors effective July 21, 2019:
- Timothy P. Walbert: Former President and CEO of Horizon Therapeutics plc with extensive experience in biopharmaceutical commercialization and leadership.
- Jeffrey L. Cleland: Co-founder and Executive Chairman of Orpheris, Inc., with a background in drug development and executive leadership at multiple biopharmaceutical firms.
Both directors will serve until the annual meeting of stockholders following the year ending December 31, 2021, or until earlier death, resignation, or removal.
Compensation and Governance Details
The new directors are subject to the Company's standard non-employee director compensation program:
- Cash Retainer: $35,000 annually per director.
- Stock Options: Each director was granted an option to purchase 43,386 shares of common stock.
- Exercise Price: $2.32 per share (closing market price on July 22, 2019).
- Vesting Schedule: Equal monthly installments over three years, contingent on continued service.
- Change in Control: Full accelerated vesting occurs upon involuntary termination without cause or for good reason within 12 months of a change in control.
No other material transactions or arrangements exist between the Company and the new directors or their immediate family members.
Investor Verification Checklist
- Verify the impact of the new board appointments on the Company's strategic direction and drug development pipeline.
- Review the definitive proxy statement on Schedule 14A (filed April 30, 2019) for full details on the director compensation program.
- Monitor future filings for any changes in the Company's financial status or operational milestones.
- Confirm the vesting status of the granted stock options in subsequent quarterly reports.